NovoCure Limited (NVCR) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
54/105
2.6 / 5 stars
All 105 Win/Lose results and 15 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinNVCR / S&P 38.99% / 15.20% |
LoseNVCR / S&P 10.95% / 15.00% |
LoseNVCR / S&P -16.67% / 50.40% |
| 2026-Q10/3 |
LoseNVCR / S&P -15.70% / -4.33% |
LoseNVCR / S&P 8.48% / 11.30% |
LoseNVCR / S&P 1.32% / 27.70% |
| 2025-Q40/3 |
LoseNVCR / S&P 0.08% / 2.65% |
LoseNVCR / S&P 8.28% / 9.00% |
LoseNVCR / S&P -21.79% / 13.40% |
| 2025-Q32/3 |
LoseNVCR / S&P -27.42% / 8.12% |
WinNVCR / S&P 11.17% / 4.61% |
WinNVCR / S&P 15.83% / 13.45% |
| 2025-Q21/3 |
LoseNVCR / S&P -0.11% / 10.94% |
WinNVCR / S&P 14.58% / 4.83% |
LoseNVCR / S&P -0.64% / 10.63% |
| 2025-Q11/3 |
LoseNVCR / S&P -40.20% / -4.27% |
WinNVCR / S&P 18.27% / 4.98% |
LoseNVCR / S&P -16.11% / 10.57% |
| 2024-Q42/3 |
WinNVCR / S&P 90.66% / 2.41% |
WinNVCR / S&P 18.82% / 5.25% |
LoseNVCR / S&P -19.59% / 6.15% |
| 2024-Q31/3 |
LoseNVCR / S&P -8.76% / 5.89% |
WinNVCR / S&P 14.63% / 5.89% |
LoseNVCR / S&P -24.86% / 6.11% |
| 2024-Q22/3 |
WinNVCR / S&P 9.60% / 4.28% |
WinNVCR / S&P 8.33% / 5.38% |
LoseNVCR / S&P -4.27% / 5.12% |
| 2024-Q11/3 |
LoseNVCR / S&P 4.69% / 10.56% |
LoseNVCR / S&P 0.61% / 5.71% |
WinNVCR / S&P 35.34% / 5.59% |
| 2023-Q41/3 |
LoseNVCR / S&P -7.55% / 11.69% |
LoseNVCR / S&P -5.30% / 6.81% |
WinNVCR / S&P 122.99% / 7.78% |
| 2023-Q31/3 |
LoseNVCR / S&P -61.08% / -3.27% |
LoseNVCR / S&P -7.12% / 7.52% |
WinNVCR / S&P 140.26% / -5.03% |
| 2023-Q21/3 |
LoseNVCR / S&P -30.99% / 8.74% |
LoseNVCR / S&P -6.89% / 9.50% |
WinNVCR / S&P 152.31% / -8.57% |
| 2023-Q11/3 |
LoseNVCR / S&P -18.01% / 7.50% |
LoseNVCR / S&P -2.86% / 10.77% |
WinNVCR / S&P 137.50% / -15.69% |
| 2022-Q41/3 |
LoseNVCR / S&P -3.46% / 7.56% |
LoseNVCR / S&P 0.53% / 11.88% |
WinNVCR / S&P 55.36% / -17.99% |
| 2022-Q32/3 |
WinNVCR / S&P 9.32% / -4.88% |
LoseNVCR / S&P -0.58% / 13.47% |
WinNVCR / S&P 185.19% / -1.41% |
| 2022-Q21/3 |
LoseNVCR / S&P -16.11% / -16.10% |
LoseNVCR / S&P 0.07% / 13.71% |
WinNVCR / S&P 1200.00% / 11.04% |
| 2022-Q11/3 |
WinNVCR / S&P 10.35% / -4.60% |
LoseNVCR / S&P 2.02% / 15.97% |
LoseNVCR / S&P -609.09% / 42.23% |
| 2021-Q40/3 |
LoseNVCR / S&P -35.37% / 11.03% |
LoseNVCR / S&P 8.23% / 15.00% |
LoseNVCR / S&P -394.74% / 96.40% |
| 2021-Q31/3 |
LoseNVCR / S&P -47.63% / 0.58% |
WinNVCR / S&P 21.38% / 10.77% |
LoseNVCR / S&P -235.00% / 69.42% |
| 2021-Q22/3 |
WinNVCR / S&P 67.82% / 8.55% |
WinNVCR / S&P 33.19% / 6.58% |
LoseNVCR / S&P -138.46% / 51.81% |
| 2021-Q12/3 |
LoseNVCR / S&P -23.61% / 6.17% |
WinNVCR / S&P 38.81% / -1.06% |
WinNVCR / S&P 10.00% / 7.39% |
| 2020-Q42/3 |
WinNVCR / S&P 55.46% / 12.15% |
WinNVCR / S&P 40.72% / -3.72% |
LoseNVCR / S&P -371.43% / -33.42% |
| 2020-Q32/3 |
WinNVCR / S&P 87.71% / 8.93% |
WinNVCR / S&P 39.75% / -2.04% |
LoseNVCR / S&P -168.97% / -27.10% |
| 2020-Q21/3 |
LoseNVCR / S&P -11.94% / 20.54% |
WinNVCR / S&P 38.92% / -0.46% |
LoseNVCR / S&P -129.55% / -27.11% |
| 2020-Q11/2 |
LoseNVCR / S&P -20.09% / -19.60% |
WinNVCR / S&P 41.07% / 3.47% |
No dataNVCR / S&P / -14.75% |
| 2019-Q42/2 |
WinNVCR / S&P 12.69% / 9.07% |
WinNVCR / S&P 41.62% / 5.36% |
No dataNVCR / S&P / 2.99% |
| 2019-Q32/2 |
WinNVCR / S&P 18.27% / 1.70% |
WinNVCR / S&P 38.66% / 5.02% |
No dataNVCR / S&P / 0.21% |
| 2019-Q22/2 |
WinNVCR / S&P 31.26% / 4.30% |
WinNVCR / S&P 35.44% / 6.64% |
No dataNVCR / S&P / 8.65% |
| 2019-Q12/2 |
WinNVCR / S&P 43.88% / 13.65% |
WinNVCR / S&P 38.60% / 8.12% |
No dataNVCR / S&P / 14.29% |
| 2018-Q41/2 |
LoseNVCR / S&P -36.11% / -13.52% |
WinNVCR / S&P 40.13% / 9.05% |
No dataNVCR / S&P / 18.23% |
| 2018-Q32/2 |
WinNVCR / S&P 67.41% / 7.71% |
WinNVCR / S&P 51.07% / 10.21% |
No dataNVCR / S&P / 19.06% |
| 2018-Q22/2 |
WinNVCR / S&P 43.58% / 3.43% |
WinNVCR / S&P 73.69% / 9.03% |
No dataNVCR / S&P / 14.46% |
| 2018-Q12/2 |
WinNVCR / S&P 7.92% / -0.76% |
WinNVCR / S&P 85.52% / 7.68% |
No dataNVCR / S&P / 12.46% |
| 2017-Q41/2 |
LoseNVCR / S&P 1.76% / 6.64% |
WinNVCR / S&P 113.57% / 7.03% |
No dataNVCR / S&P / 13.82% |
| 2017-Q32/2 |
WinNVCR / S&P 14.74% / 4.48% |
WinNVCR / S&P 136.21% / 5.68% |
No dataNVCR / S&P / 17.57% |
| 2017-Q22/2 |
WinNVCR / S&P 113.58% / 3.09% |
WinNVCR / S&P 139.30% / 4.83% |
No dataNVCR / S&P / 17.74% |
| 2017-Q11/2 |
LoseNVCR / S&P 3.18% / 6.07% |
WinNVCR / S&P 155.83% / 3.67% |
No dataNVCR / S&P / 13.32% |
| 2016-Q41/2 |
LoseNVCR / S&P -8.08% / 3.82% |
WinNVCR / S&P 150.52% / 2.09% |
No dataNVCR / S&P / 7.05% |
| 2016-Q31/2 |
LoseNVCR / S&P -26.82% / 3.85% |
WinNVCR / S&P 165.37% / 0.20% |
No dataNVCR / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NVCR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 45.90% | 20.78% |
| Annualized return | 45.90% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NVCR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -86.92% | 83.14% |
| Annualized return | -33.43% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | NVCR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 132.13% | 319.30% |
| Annualized return | 8.79% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |